

Amendment and Reply to Office Action

Application No. 09/658,699

Attorney's Docket No. DX01042X

(033347-009)

Page 2

### **SUMMARY OF AMENDMENTS**

In the Claims:

Claims 51-62 are pending prior to the amendments.

Claims 59-62 are being canceled, and claims 51 and 55 are being amended.

After the amendments, claims 51-58 will be pending.

**CLAIM LIST**

1.-50. Canceled.

51. (Currently amended) A binding compound comprising an antigen binding site from an antibody, which specifically binds to a mammalian IL-B30/p40 complex, said complex comprising an IL-B30 subunit (SEQ ID NO:2 or 4) and a p40 subunit of human or murine origin, wherein said antibody binds an epitope presented by the IL-B30/p40 complex, ~~but exhibits less than 10% crossreactivity with any epitope presented by either~~ but not IL-B30 alone or p40 alone.

52. (Previously amended) The binding compound of claim 51, wherein said binding compound is a humanized antibody, monoclonal antibody, single chain antibody, Fv fragment, Fab fragment, Fab' fragment, or F(ab')<sub>2</sub> fragment.

53. (Previously amended) The binding compound of claim 51, wherein said binding compound is a neutralizing antibody.

54. (Previously amended) A composition comprising the binding compound of claim 51 and a pharmaceutically acceptable carrier or diluent.

55. (Currently amended) A binding compound comprising an antigen binding site from an antibody, which specifically binds to a fusion protein comprising an IL-B30 subunit (SEQ ID NO:2 or 4) and a p40 subunit of human or murine origin, wherein said antibody binds an epitope presented by said fusion protein, ~~but exhibits less than 10% crossreactivity with any epitope presented solely by either~~ but not IL-B30 alone or p40 alone.

56. (Previously amended) The binding compound of claim 55, wherein said binding compound is a humanized antibody, monoclonal antibody, single chain antibody, Fv fragment, Fab fragment, Fab' fragment, or F(ab')<sub>2</sub> fragment.

57. (Previously amended) The binding compound of claim 55, wherein said binding compound is a neutralizing antibody.

58. (Previously amended) A composition comprising the binding compound of claim 55 and a pharmaceutically acceptable carrier or diluent.

59.-62. Canceled.